RAPT Therapeutics (RAPT Therapeutics) EPS (Diluted) : $-3.08 (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is RAPT Therapeutics EPS (Diluted)?

RAPT Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.79. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.08.

RAPT Therapeutics's EPS (Basic) for the three months ended in Mar. 2024 was $-0.79. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.08.

RAPT Therapeutics's EPS without NRI for the three months ended in Mar. 2024 was $-0.79. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.08.

During the past 3 years, the average EPS without NRIGrowth Rate was -11.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 5.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 7 years, RAPT Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 36.10% per year. The lowest was -11.70% per year. And the median was -4.70% per year.

RAPT Therapeutics EPS (Diluted) Historical Data

The historical data trend for RAPT Therapeutics's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RAPT Therapeutics EPS (Diluted) Chart

RAPT Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

Get a 7-Day Free Trial

-9.89

-2.19

-2.53

-2.58

-3.05

RAPT Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EPS (Diluted)	Get a 7-Day Free Trial															-0.76	-0.66	-0.82	-0.81	-0.79

Competitive Comparison of RAPT Therapeutics's EPS (Diluted)

For the Biotechnology subindustry, RAPT Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RAPT Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RAPT Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where RAPT Therapeutics's PE Ratio falls into.

RAPT Therapeutics EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

RAPT Therapeutics's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-116.798	-	0)	/	38.338
	=	-3.05

RAPT Therapeutics's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-30.521	-	0)	/	38.625
	=	-0.79

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.08

RAPT Therapeutics (NAS:RAPT) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

RAPT Therapeutics EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of RAPT Therapeutics's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

RAPT Therapeutics (RAPT Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RAPT Therapeutics Inc (NAS:RAPT) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

0RA:Germany

Address

561 Eccles Avenue, South San Francisco, CA, USA, 94080

Website

https://www.rapt.com

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Executives

Dirk G. Brockstedt	officer: Chief Scientific Officer	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
William Ho	officer: Chief Medical Officer	561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA 94080
Wendye Robbins	director	C/O RAPT THERAPEUTICS, INC., 561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA 94080
Column Group Ii, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Tcg Iv Gp, Llc	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iv Gp, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iv, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iv-a, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Rodney Kb Young	officer: Chief Financial Officer	STEMCELLS, INC., 3155 PORTER DRIVE, PALO ALTO CA 94304
Lori Lyons-williams	director	C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Column Group Llc	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Ponoi Ii Management, Llc	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Ponoi Capital Ii, Lp	10 percent owner	1700 OWENS STREET, STE 500, SAN FRANCISCO CA 94158
Ponoi Management, Llc	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Ponoi Capital, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158